Compare Amphastar Pharmaceuticals Inc (AMPH) vs Manchester United PLC (MANU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Manchester United PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Manchester United PLC trades at $22.28 (market cap $3.80B). The key difference: Manchester United PLC is far larger — about 4.6× Amphastar Pharmaceuticals Inc's market cap, and Manchester United PLC pays a 1.26% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MANU | |
|---|---|---|
Market Cap | $826.08M | $3.80B |
Sector | Health | Media |
52-Week High | $30.81 | $23.53 |
52-Week Low | $16.87 | $15.10 |
Enterprise Value | $1.22B | $4.72B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Manchester United (MANU) trades at $22.04, up 0.18% today, with a bullish technical signal and positive news flow around stadium development. The company reported mixed quarterly earnings but achieved Champions League qualification, boosting future revenue prospects. However, fundamentals show persistent net losses and negative ROE, with a high P/B ratio of 16.05 indicating premium valuation despite profitability challenges.
The outlook is cautiously optimistic, driven by stadium expansion plans and improved sporting performance, but significant execution risks and ongoing financial losses warrant careful monitoring. Analyst sentiment is mixed with 40% buy ratings, reflecting the balance between growth potential and current weak profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
